This idea is supported by the observed low levels of PSA, a clinical biomarker for AD efficacy, despite elevated AR mRNA and protein levels when TRX1 is inhibited in the in vivo castrate setting (Figs. 5 and 6). Here, TXN is linked to Alzheimer disease.